新藥物可溶解動脈中的脂肪，可預防猝死或中風
原文地址：https://www.abdn.ac.uk/news/11280/
正文翻譯：
Drug "melts away" fat inside arteries
新藥物可「融化」動脈中的脂肪
A new drug being trialled for treating breast cancer and diabetes has been shown to "melt away" the fat inside arteries that can cause heart attacks and strokes.
一種用於治療乳腺癌和糖尿病的新藥物已經被證明可以「融化」動脈中的脂肪，這些脂肪可能導致心臟病或中風。
Researchers from the University of Aberdeen, using pre-clinical mouse models, showed that just a single dose of the drug (Trodusquemine) completely reversed the effects of a disease that causes a host of heart problems.
阿伯丁大學(University of Aberdeen)的研究人員使用臨床前小鼠模型顯示，只需一劑這種藥物(Trodusquemine)就完全逆轉了這種可引發一系列心臟問題的疾病。
Atherosclerosis is the build-up of fatty material inside the arteries.
動脈粥樣硬化是動脈內脂肪物質的堆積所造成的。
Over time this fatty material can grow bigger until your arteries become so narrow that not enough blood can pass through.
隨著時間的推移，這種脂肪堆積會變得越來越多，直到你的動脈變得太過狹窄，以至於血液無法通過此處。
Atherosclerosis is the condition that causes most heart attacks and strokes.
動脈粥樣硬化是引起心臟病和中風的主要原因。
In pre-clinical tests, mice with set-in atherosclerosis, mimicking what happens in humans, had less fatty plaques in their arteries whether they had regular doses over time or just a single dose of Trodusquemine.
臨床前研究中患有動脈粥樣硬化的小白鼠，不管是服用了規律計量的或者僅僅是一劑Trodusquemine的小白鼠動脈中的脂肪都得到了減少。
The drug works by stopping an enzyme called PTP1B, which is normally increased in people with obesity or diabetes and conditions involving prolonged inflammation such as sepsis, inflamed diabetic foot ulcers and allergic lung inflammation. The researchers found that it also stimulated the action of another protein (AMPK), which effectively mimics exercise and reduces chronic inflammation.
這種藥物通過阻止一種叫做PTP1B的酶來工作，這種酶通常在患有肥胖症或糖尿病的人群中增加，以及包括膿毒症、糖尿病發炎引起的足潰瘍和過敏性肺炎等長期炎症。研究人員發現，它還能刺激另一種蛋白質(AMPK)的作用，它能有效地模擬人體鍛煉，減少慢性炎症的發生。
「As you age you start to develop these fatty streaks inside your arteries. It is a big problem for people who are overweight or have underlying cardiovascular conditions."--Professor Mirela Delibegovic
「隨著年齡的增長，這些脂肪條紋開始在你的動脈中形成。對於超重或有潛在心血管疾病的人來說，這可是一個大問題。」--邁瑞拉 迪里伯維克教授
It has already been shown to be effective with diabetes and breast cancer patients but this is the first time the drug has been shown to have benefits for long-term cardiovascular disease.
它已經被證明對糖尿病和乳腺癌患者有效，但這是第一次證明該藥物對長期心血管疾病有好處。
The ￡236,000 study was funded by the British Heart Foundation.
該研究收到了英國心臟基金會236,000磅的資助。
Professor Mirela Delibegovic and Dr Dawn Thompson from the University of Aberdeen』s Institute of Medical Sciences who led the study said: 「All humans have some level of atherosclerosis. As you age you start to develop these fatty streaks inside your arteries. It is a big problem for people who are overweight or have underlying cardiovascular conditions.」
來自阿伯丁大學醫學科學研究所的邁瑞拉 迪里伯維克教授和多恩 湯普森博士領導了這項研究，他說:「所有人都有一定程度的動脈粥樣硬化。隨著年齡的增長，你的動脈中開始形成這些脂肪條紋。對於超重或有潛在心血管疾病的人來說，這可是一個大問題。
「Trodusquemine has already been trialled for treatment of diabetes and breast cancer but this is the first time it has been used in models of atherosclerosis.
「Trodusquemine已經被用於治療糖尿病和乳腺癌，但這是它第一次被用於治療動脈粥樣硬化的例子。」
「These have only been tested at pre-clinical level, in mice, so far but the results were quite impressive and showed that just a single dose of this drug seemed to completely reverse the effects of arthrosclerosis.
「目前為止這些藥物只在小鼠的臨床前水平測試過，但結果非常震撼，僅僅一劑這種藥物似乎完全扭轉了動脈粥樣硬化的效果。」
「The next step is to test the ability of this drug to improve outcomes in human patients with developed atherosclerosis and cardiovascular disease」.
「下一步是測試這種藥物是否能治療患有動脈粥樣硬化和心血管疾病的人類患者。」
Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation, said: 「Trodusquemine is in early clinical trials for the treatment of diabetes. This study shows it can also limit the build-up of fatty atherosclerotic plaques in mice. If we see the same effect in patients, the drug may prove even more useful than currently hoped for.」
英國心臟基金會的副醫學主任傑里米·皮爾森教授說:「Trodusquemine正處於糖尿病治療的早期臨床試驗中。」這項研究表明，它也可以限制在小鼠中脂肪動脈粥樣硬化斑塊的形成。如果我們在病人身上看到同樣的效果，這種藥物可能比目前所期望的更加有用。
